Screener
Shattuck Labs, Inc. STTK SL-325 — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Shattuck Labs, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 6:57 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-055483
| Revenue | Three Months Ended June 30, 2026 / $ | Three Months Ended June 30, 2026 / — | Three Months Ended June 30, 2025 / $ | Three Months Ended June 30, 2025 / — |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development: | ||||
| SL-3251 | 4,107 | 2,604 | ||
| SL-8461 | 1,679 | — | ||
| Other research and development2 | 2,479 | 2,878 | ||
| Research and development non-equity compensation | 2,360 | 2,331 | ||
| Research and development equity compensation | 1,075 | 867 | ||
| Total research and development | 11,700 | 8,680 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is Shattuck Labs, Inc.'s SL-325 — R&D?
- Shattuck Labs, Inc. (STTK) reported SL-325 — R&D of $4.11M in Q2 2026.
- How has Shattuck Labs, Inc.'s SL-325 — R&D changed year-over-year?
- Shattuck Labs, Inc.'s SL-325 — R&D increased by 57.7% year-over-year, from $2.6M to $4.11M.
- What does SL-325 — R&D mean?
- This metric represents the direct operating expenses allocated to the research, clinical development, and preclinical testing of the SL-325 product candidate. It captures the investment required to advance this specific therapeutic asset through the drug development pipeline, including costs for clinical trials, manufacturing process development, and regulatory activities. Monitoring this spend provides insight into the company's capital allocation strategy and the pace of development for this particular pipeline asset.
Ask your AI about Shattuck Labs, Inc.'s sl-325 — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude